A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant with or without LY2835219, a CDK4/6 Inhibitor, for Women with Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
A study for women with metastatic breast cancer using study drug LY2835219 for treatment
Sponsor: Eli Lilly and Company
Enrolling: Female Patients Only
IRB Number: AAAN8657
U.S. Govt. ID: NCT02107703
Contact: Meghna Trivedi MD: 2123050170 / mt2134@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see how safe investigational drug, LY2835219 is and how well it will work to help people with advanced hormone receptor (HR) positive, HER2 negative breast cancer. This study will investigate whether the combination of LY2835219 plus fulvestrant improves outcomes compared to fulvestrant alone for women with a certain type of advanced breast cancer.
This study is closed
Investigator
Meghna Trivedi, MD
Do You Qualify?
Do you have a diagnosis of HR+ or HER2- breast cancer? Yes No
Are you currently receiving any investigational drugs in a clinical trial? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Meghna Trivedi MD
mt2134@cumc.columbia.edu
2123050170
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE